Ensartinib before surgery for ALK-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether taking ensartinib before surgery can help people with a specific type of lung cancer that has the ALK gene change. It is for those whose cancer is stage II or III and can be surgically removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have lung adenocarcinoma (a type of non-small cell lung cancer) that is stage II or III and can be removed with surgery.
- Your cancer must test positive for the ALK gene change.
- You must be between 18 and 75 years old.
- You must be in generally good health, able to perform daily activities without help, and have adequate organ function.
- You must not have received any prior cancer treatment for this cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests whether ensartinib given after surgery can lower the risk of lung cancer coming back in people with ALK-positive non-small cell lung cancer. You may be eligible if your tumor was completely removed and your recovery and lab tests meet specific requirements.
This trial studies whether taking ensartinib (a targeted pill) after lung cancer surgery can lower the chance the cancer comes back. It is for people with ALK-positive non-small cell lung cancer (NSCLC) whose cancer has been fully removed and who have recovered from treatment.
This trial compares ensartinib with standard platinum-based chemotherapy as “adjuvant” treatment—medicine given after surgery to lower the chance the cancer comes back. It’s for people with stage IIA to IIIA ALK-positive non-small cell lung cancer who had their tumor surgically removed.
This trial tests whether taking lazertinib before surgery can shrink or control EGFR-mutant lung adenocarcinoma that can be fully removed by an operation. It uses a special liquid biopsy from fluid in the lungs to confirm the EGFR mutation and guide treatment.
This trial tests a combination of two targeted drugs (BL-B01D1 and almonertinib) given before surgery to shrink EGFR-mutated lung cancer. The goal is to make surgery more effective and possibly improve long-term outcomes.
This trial tests a targeted therapy pill called ensartinib given before surgery for people with ALK-positive lung cancer. The goal is to see if it can shrink the tumor enough to make surgery more successful.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.